X4 Pharmaceuticals Soars 9.21% on Bullish Sentiment

On July 17, 2025, X4 Pharmaceuticals' stock surged by 9.21% in pre-market trading, reflecting a significant bullish sentiment among investors.

Analysts have given X4 Pharmaceuticals a consensus rating of Buy, with an average rating score of 3.00. This rating is based on three buy ratings, indicating a strong positive outlook for the company's future performance.

The company's stock has also seen a reverse split, where shareholders now hold one share for every 30 previously held. This move is often seen as a strategy to boost the stock price and attract more investors.

Despite the recent surge, the company's stock has faced challenges in the past, with a 30-day loss of 45.52%. However, the current performance indicates a potential turnaround, with a 24-hour gain of 13.16% and a 7-day change of -12.14%.